Gastric cancer and colorectal cancer have something in common

Share This Post

Researchers at the Duke University Cancer Institute have found that H. pylori may lead to an increased risk of colorectal cancer, especially for people with color. People of color are more likely to be diagnosed and die of colorectal cancer.

The researchers further explored the link between H. pylori and colorectal cancer. More than half of the world’s population is infected with Helicobacter pylori, bacteria can cause gastric cancer and gastric ulcers. Researchers at Duke University collected samples from subjects of different races and checked antibody levels before cancer developed. Half of the more than 8,000 study participants continue to develop colorectal cancer. To determine whether the presence of antibodies increased the likelihood of developing colorectal cancer, the researchers compared the frequency of antibodies between cancer and non-cancer subjects. They observed similar rates of past infections in the two groups. As a result, a higher percentage of black and Latino subjects had H. pylori antibodies. This finding is consistent in both cancer and non-cancer tissues. Antibodies specific for Helicobacter pylori proteins are most commonly found in different ethnic groups. Most importantly, a high-level antibody to the H. pylori protein-VacA protein is closely related to the incidence of colorectal cancer in African-American and Asian Americans. 

The association between H. pylori and colorectal cancer plays a role in people of color and can significantly affect treatment options, action plans, and public health differences related to cancer. Medical professionals can identify high-risk people with colorectal cancer based on the status of Helicobacter pylori and reduce the incidence of cancer through treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy for AIDS related B Cell malignancies
Aids cancer

CAR T Cell therapy for AIDS related B-Cell malignancies

CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient’s T cells to express chimeric antigen receptors (CARs) targeting CD19 on B cells. This treatment holds promise in eradicating malignant B cells but must carefully manage immunosuppression in HIV-positive individuals.

Cancer statistics in India 2024
Cancer

Cancer statistics in India 2024: Incidence, estimates and projections

In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most prevalent among women and men, respectively. Sadly, many cases are diagnosed late, impacting survival rates. Improved awareness and access to healthcare are crucial. By 2030, cancer incidence is expected to surpass 1.7 million cases annually. Efforts to enhance prevention, early detection, and treatment access are crucial to mitigate this growing burden. Check our cancer statistics in India for 2024 and future projections.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy